Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Milne

Showing results (1-10 of 88) with videos related to

Pageof 9
Sort By:
The New Zealand Medical Journal|May 12, 2005
Valuing prevention: discounting health benefits and costs in New ZealandRichard Milne
BMJ (Clinical Research Ed.)|November 2, 2002
New heart risk equations do not affect existing guidelinesRichard Milne
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 10, 2020
Societal considerations in host genome testing for COVID-19Richard Milne
Social Studies of Science|August 2, 2012
Pharmaceutical prospects: biopharming and the geography of technological expectationsRichard Milne
The New Zealand Medical Journal|September 1, 2005
Richard Milne responds to PHARMAC on discounting future health benefits and costsRichard Milne
New Genetics and Society|April 8, 2020
The rare and the common: scale and the genetic imaginary in Alzheimer's disease drug developmentRichard Milne
Sociology of Health & Illness|September 26, 2021
Lived time and the affordances of clinical research participationNatassia Brenman, Richard Milne
Pharmacoeconomics|December 18, 2021
CHEERS to 30 Years of PharmacoEconomicsRichard Milne, Christopher Carswell
Health Policy (Amsterdam, Netherlands)|February 25, 2014
Is there any evidence that the Trans Pacific Partnership Agreement will threaten access to affordable medicines and health equity in New Zealand?Michael Wonder, Richard Milne
Expert Review of Pharmacoeconomics & Outcomes Research|October 13, 2009
Should rotavirus vaccines be included in the national immunization program of a small developed country?Richard Milne, Keith Grimwood
Pageof 9

Showing results (1-10 of 88) with videos related to

Sort By:
Pageof 9
The New Zealand Medical Journal|May 12, 2005
Valuing prevention: discounting health benefits and costs in New ZealandRichard Milne
BMJ (Clinical Research Ed.)|November 2, 2002
New heart risk equations do not affect existing guidelinesRichard Milne
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 10, 2020
Societal considerations in host genome testing for COVID-19Richard Milne
Social Studies of Science|August 2, 2012
Pharmaceutical prospects: biopharming and the geography of technological expectationsRichard Milne
The New Zealand Medical Journal|September 1, 2005
Richard Milne responds to PHARMAC on discounting future health benefits and costsRichard Milne
New Genetics and Society|April 8, 2020
The rare and the common: scale and the genetic imaginary in Alzheimer's disease drug developmentRichard Milne
Sociology of Health & Illness|September 26, 2021
Lived time and the affordances of clinical research participationNatassia Brenman, Richard Milne
Pharmacoeconomics|December 18, 2021
CHEERS to 30 Years of PharmacoEconomicsRichard Milne, Christopher Carswell
Health Policy (Amsterdam, Netherlands)|February 25, 2014
Is there any evidence that the Trans Pacific Partnership Agreement will threaten access to affordable medicines and health equity in New Zealand?Michael Wonder, Richard Milne
Expert Review of Pharmacoeconomics & Outcomes Research|October 13, 2009
Should rotavirus vaccines be included in the national immunization program of a small developed country?Richard Milne, Keith Grimwood
Pageof 9